Alpha Cognition Inc
ACOG
Rangering i aksjer
#20188
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Aksjekurs
$8.47
Sist synkronisert: 2026-10-19
Markedsverdi
$131.47M
Endring (1 dag)
3.36%
Endring (1 år)
68.29%
Land
US
Handel Alpha Cognition Inc (ACOG)
Kategori
Healthcare
Inntekter for Alpha Cognition Inc (ACOG)
Inntekter i Jun 2026 TTM: 0.00
Ifølge Alpha Cognition Inc sine nyeste økonomiske rapporter er selskapets nåværende resultat 0.00. I 2022 hadde selskapet et resultat på $-12.11M, en økning sammenlignet med resultatet i 2021, som var $-19.55M. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Alpha Cognition Inc fra 2018 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2023 | $-13.77M | 13.68% |
| 2022 | $-12.11M | -38.02% |
| 2021 | $-19.55M | 237.90% |
| 2020 | $-5.78M | -12.45% |
| 2019 | $-6.61M | 20,254.71% |
| 2018 | $-32.46K | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
